Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2024-04-26 12:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
2024-04-25 23:50:27 ET Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript April 25, 2024 02:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Hiroyuki Okuzawa - Representative Director, President and COO ...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-25 08:37:36 ET More on AstraZeneca AstraZeneca: What The Market's Missing What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca beats top-line and bottom-line estimates; ...
2024-04-25 06:33:53 ET More on Daiichi Sankyo Daiichi Sankyo Company, Limited (DSKYF) Q3 2023 Earnings Call Transcript Daiichi Sankyo Company, Limited 2023 Q3 - Results - Earnings Call Presentation AstraZeneca's Enhertu granted approval for HER-2 positive tumor-agnos...
2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...
2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...
2024-04-09 08:54:46 ET More on Vincerx Pharma Vincerx Pharma GAAP EPS of -$0.23 beats by $0.06 Seeking Alpha’s Quant Rating on Vincerx Pharma Historical earnings data for Vincerx Pharma Financial information for Vincerx Pharma Read the full a...
2024-04-05 16:14:43 ET More on AstraZeneca, Daiichi Sankyo What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca Imfinzi im...
2024-04-02 16:39:37 ET Summary After a forgettable last year, Merck & Co., Inc.'s stock price is up 20% YTD, supported by approvals, a positive outlook for 2024, and an attractive forward P/E. Keytruda, the company's top-selling treatment, received approval from the European C...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...